NCT06242691 2026-03-06
MK-1200-002
Merck Sharp & Dohme LLC
Phase 1/2 Completed
Clinical Trials
6 trialsNCT03448393 2025-06-04
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04847050 2024-08-27
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02509143 2024-08-12
AcuPONV
Pusan National University Yangsan Hospital
Phase NA Completed
NCT02780609 2022-11-04
Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT00401388 2018-03-07
A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas
AEterna Zentaris
Phase 2 Completed